Quick Facts Cryptococcus gattii, Scientific classification ...

Cryptococcus gattii
Cryptococcus neoformans weakly encapsulated (left) as it appears in nature, and (right) rehydrated with thick polysaccharide capsule as it appears once in the lungs.
Scientific classification
Domain:	Eukaryota
Kingdom:	Fungi
Division:	Basidiomycota
Class:	Tremellomycetes
Order:	Tremellales
Family:	Cryptococcaceae
Genus:	Cryptococcus
Species:	C. gattii
Binomial name
Cryptococcus gattii (Vanbreus. & Takashio) Kwon-Chung & Boekhout

Close

Cryptococcus gattii, formerly known as Cryptococcus neoformans var. gattii, is an encapsulated yeast found primarily in tropical and subtropical climates. Its teleomorph is Filobasidiella bacillispora, a filamentous fungus belonging to the class Tremellomycetes.

C. gattii is one of two organisms causing the infectious disease cryptococcosis (along with C. neoformans).^[1] Clinical manifestations of C. gattii infection include pulmonary cryptococcosis (lung infection), basal meningitis, and cerebral cryptococcomas. Occasionally, the fungus is associated with skin, soft tissue, lymph node, bone, and joint infections. In recent years, it has appeared in British Columbia, Canada and the Pacific Northwest.^[2] It has been suggested that tsunamis, such as the 1964 Alaska earthquake and tsunami, might have been responsible for carrying the fungus to North America and its subsequent spread there.^[3] From 1999 through to early 2008, 216 people in British Columbia have been infected with C. gattii, and eight died from complications related to it.^[4] The fungus also infects animals, such as dogs, koalas, and dolphins.^[5] In 2007, the fungus appeared for the first time in the United States, in Whatcom County, Washington^[6] and in April 2010 had spread to Oregon.^[7] The most recently identified strain, designated VGIIc, is particularly virulent, having proved fatal in 19 of 218 known cases.^[8]

Cryptococcus gattii has recently been divided into five species.^[9] These are C. gattii, C. bacillisporus, C. deuterogattii, C. tetragattii, and C. decagattii.

C. gattii occupies an environmental niche in decaying hollows of trees native to tropical as well as subtropical and temperate regions. It may then contaminate nearby soil or persist in wood products.^[1]

C. gattii infections were initially thought to be restricted to tropical^[1][12] and subtropical regions.^[12] C. gattii is the predominant cause of cryptococcosis in sub-Saharan Africa.^[13] The highest incidences of C. gattii infections occur in Papua New Guinea and Northern Australia. However cases have been reported in various other regions including Brazil, India and the Pacific Northwest of North America.^{[citation needed]}

In the United States, C. gattii serotype B, subtype VGIIa, is largely responsible for clinical cases. The VGIIa subtype was responsible for the outbreaks in Canada; it then appeared in the U.S. Pacific Northwest.^{[citation needed]}

According to a CDC summary, from 2004 to 2010, 60 cases were identified in the U.S.: 43 in Oregon, 15 in Washington, and one each in Idaho and California. Slightly more than half of these cases were immunocompromised; 92% of all isolates were of the VGIIa subtype. In 2007, the first case in North Carolina was reported, subtype VGI, which is identical to the isolates found in Australia and California.^{[citation needed]}

The multiple clonal clusters in the Pacific Northwest likely arose independently of each other as a result of sexual reproduction occurring within the highly sexual VGII population.^[14] VGII C. gattii have probably undergone either bisexual or unisexual reproduction in multiple different locales, thus giving rise to novel virulent phenotypes.

C. gattii notable for more causing cryptococcosis even in immunocompetent^[12]/otherwise healthy individuals.^[1] Unlike Cryptococcus neoformans, C. gattii is not particularly associated with human immunodeficiency virus infection or other forms of immunosuppression. Increased virulence may be related to its capability to rapidly proliferate within lymphocytes.^[15]

C. gattii infection is more likely to be limited to the lung (rather than disseminating to the CNS). When CNS infection does occur, it may involve more localised lesions (cryptococcomas) rather than the diffuse infection characteristic of C. neoformans.^[12]

Culture of sputum, bronchoalveolar lavage, lung biopsy, cerebrospinal fluid or brain biopsy specimens on selective agar allows differentiation between the five members of the C. gattii species complex and the two members of the C. neoformans species complex.

Medical treatment consists of prolonged intravenous therapy (for 6–8 weeks or longer) with the antifungal drug amphotericin B, either in its conventional or lipid formulation. The addition of oral or intravenous flucytosine improves response rates. Oral fluconazole is then administered for six months or more.

Antifungals alone are often insufficient to cure C. gattii infections, and surgery to resect infected lung (lobectomy) or brain is often required. Ventricular shunts and Ommaya reservoirs are sometimes employed in the treatment of central nervous system infection.

People who have C. gattii infection need to take prescription antifungal medication for at least 6 months; usually the type of treatment depends on the severity of the infection and the parts of the body that are affected.

• For people who have asymptomatic infections or mild-to-moderate pulmonary infections, the treatment is usually fluconazole.
• For people who have severe lung infections, or infections in the central nervous system (brain and spinal cord), the treatment is amphotericin B in combination with flucytosine.^[16]

• Jenney A, Pandithage K, Fisher DA, Currie BJ (2004). "Cryptococcus infection in Tropical Australia". Journal of Clinical Microbiology. 42 (8): 3865–3868. CiteSeerX 10.1.1.627.3222. doi:10.1128/jcm.42.8.3865-3868.2004. PMC 497626. PMID 15297551.